Drug intelligence / Profile preview

BEBT-758

Development stage: Preclinical
Lead developer: BeBetter Med
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

BEBT-758 is a small interfering RNA (siRNA) therapeutic targeting the alpha-synuclein (SNCA) gene. It is being developed by BeBetter Med for the treatment of Parkinson's disease. The drug acts as an alpha-synuclein expression inhibitor via RNA interference, aiming to reduce or prevent the pathological accumulation of alpha-synuclein protein, which is implicated in neurodegenerative processes associated with Parkinson's disease. As of early 2025, BEBT-758 remains in preclinical development[1][2].

Other names: BEBT 758BEBT758BEBT-758

Targets

Alpha-synuclein messenger RNA

Beyond the preview

Go deeper on BEBT-758.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BEBT-758.

Explore the full profile